• Hepatera Ltd., of Moscow, a biotech company that is part of Maxwell Biotech Venture Fund's portfolio, said it enrolled the first three patients with chronic hepatitis B virus (HBV) in its Phase Ib/IIa study of Myrcludex B, a drug designed to inhibit the essential HBV receptor on the liver cell surface, preventing the infection of healthy cells and viral spreading in the liver. Results are expected by the end of 2013.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter